Simcere Zaiming Entered into a Clinical Collaboration Agreement with MSD to Evaluate SIM0235 + Keytruda for Advanced Solid Tumors and Cutaneous T-cell Lymphoma
Shots:
- The companies collaborated to evaluate the safety, efficacy, PK/PD characteristics & immunogenicity of SIM0235 as monotx. & in combination with Keytruda (pembrolizumab) in the P-I trial (SIM1811-03-TNFR2-102) for advanced solid tumors and CTCL
- MSD will be responsible to supply Keytruda & collaborate with Simcere Zaiming on this study while Simcere Zaiming holds all commercial rights globally to SIM0235, a humanized IgG1 mAb targeting TNFR2 & blocks its activation by endogenous TNF
- Through the use of ADCC and ADCP, SIM0235 demonstrated a cytotoxic effect on immune suppressive cells, incl. regulatory T cells (Tregs), and bone marrow-derived suppressor cells that express the TNFR2 gene
Ref: prnewswire | Image: Simcere Zaiming
Related Post:- Simcere Entered into an Exclusive License Agreement with Idorsia for Daridorexant in China
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
